SYDNEY, Australia and FLORHAM PARK, NJ, November 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited IMUa clinical-stage immuno-oncology company, and Celularity Inc. CELU (Celularity), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies and biomaterial products, is pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with that derived from the Celularity’s placenta-derived off-the-virus present-shelf allogeneic CYCART-19 T cells was presented at the prestigious Society for Immunotherapy of Cancer (SITC) Annual Meeting held November 8-12, 2022 in Boston, USA .

dr Anthony Park from the lab of Dr. Saul Priceman in City of Hope presented the poster “CF33-CD19t oncolytic virus (onCARlytics) in Combination with off-the-shelf allogeneic CYCART-19 T-cells targeting de novo CD19t expressing tumors.”

The main findings of the presentation are as follows:

• onCARlytics can target the triple-negative breast cancer cell line MDA-MB-468 to virus-dose dependently express CD19t as a CAR-T cell target.
• CYCART-19 demonstrated efficacy in preclinical models against MDA-MB-468 expressing CD19t following onCARlytics infection.
• There was a virus dose-dependent increase in CYCART-19 activation and IL-2 production.
• After CD19t-expressing tumor killing, allogeneic CYCART-19 T cells produced less IFN-γ compared to autologous CD19 CAR T cells.
• CD19t expression was detected in tumors after onCARlytics infection in vivo.
• Treatment with CYCART-19 7 days after onCARlytics infection demonstrated significant tumor regression compared to onCARlytics or T cells alone in a mouse xenograft model of triple-negative breast cancer.

The poster is available on Imugene’s website, https://www.imugene.com/conference-presentations and the Cellularity website, https://www.celularity.com./press-releases.

Leslie Chong, CEO/MD of Imugene said, “When we partnered with Celularity, we really wanted to combine the…